You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer

Article metrics

Article menu

Download PDFPDF

Oral Plenary
Plenary V
IGCS20_1101
16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

AbstractFullPdf
Nov 20202907
Dec 20202707
Jan 2021802
Feb 2021402
Mar 20211402
Apr 20211003
May 2021201
Jun 2021502
Jul 2021003
Aug 2021006
Sep 2021005
Oct 20215017
Nov 202114018
Dec 2021801
Jan 20221801
Feb 20221002
Mar 20221801
Apr 20221200
May 20221806
Jun 2022804
Jul 20226408
Aug 20222605
Sep 20222208
Oct 20221205
Nov 20221402
Dec 20222604
Jan 20232403
Feb 20231403
Mar 20231902
Apr 20231003
May 20231200
Jun 2023600
Jul 20231005
Aug 20231201
Sep 2023404
Oct 20231201
Nov 20231603
Dec 20232500
Jan 2024201
Feb 20241201
Mar 20248017
Apr 20241606
Total5760172